Bespak ready to break with the past, maintains growth plans despite Exubera hitch
This article was originally published in Clinica
Executive Summary
A good financial performance in the year 2006-07 for UK drug delivery and anaesthesia device specialist Bespak was tempered marginally by its board's comments that the current year will be "broadly flat". This, it said, would be as a result of declining sales of valves for ozone-depleting CFC formulations in the US and a fall in production volumes of the Exubera insulin inhaler device, following slower-than-expected uptake of the device.